William K. Oh, MD - Mapping the Pathways to Better Patient Outcomes in Prostate Cancer: Personal Insights and Guidance From the Patient CaseBook - a podcast by PVI, PeerView Institute for Medical Education
from 2022-05-04T02:14:15.918002
Go online to PeerView.com/SEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the prostate cancer management landscape has become increasingly complex with the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of disease—including nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. At a recent PeerView Live CaseBook program, a panel of experts presented case vignettes to illustrate the best practice management of prostate cancer and how current clinical trends will change patient care. These case-based interludes highlighted evidence from key trials on next-generation androgen-targeting agents; the role of DNA damage-response mutations; biomarker testing and the potential role of innovative targeted therapy; and advances in immunotherapy for prostate cancer. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers, Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor-, patient-, and treatment-related factors, Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum, Summarize current evidence and ongoing research with investigational strategies, including molecularly targeted and immune checkpoint inhibitor therapies, for the management of prostate cancer.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education